Melville, New York-based Henry Schein, Inc. (HSIC) provides healthcare products and services to office-based dental and medical practitioners, and alternate sites of care worldwide. With a market cap of $8.9 billion, the company operates through Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments.

Companies valued between $2 billion and $10 billion are generally classified as “mid-cap stocks," and Henry Schein fits this criterion perfectly. The company offers a wide range of solutions, including medical and dental supplies, equipment, and cutting-edge technology products, such as practice management software and revenue cycle solutions, enhancing efficiency and delivering quality patient care.

Henry Schein currently trades 11.8% below its 52-week high of $82.49 recorded on Feb. 5. HSIC's stock has gained 4.9% over the past three months, outpacing the broader Dow Jones Industrial Average's ($DOWI) marginal rise.

Longer term, Henry Schein’s stock has surged 5.2% on a YTD basis, whereas the Dow has increased 1%. Moreover, shares of HSIC soared 10.1% over the past 52 weeks, slightly outperforming the Dow Jones’ 9.9% returns over the same time frame.

The stock has risen above its 50-day moving average since early May and traded along its flat 200-day moving average in recent weeks.

Henry Schein’s stock rose 2% following the release of its mixed Q1 2025 results on May 5. The company reported net sales of $3.2 billion, a marginal decline from the year-ago quarter, missing the consensus estimate. However, its net sales rose 1.4% on a constant currency basis. The Global Technology segment recorded 3.2% growth, driven by demand for practice management systems and revenue cycle management products. Meanwhile, its adjusted EPS grew 4.5% from the prior-year quarter to $1.15, surpassing analysts’ estimate by 3.6%.

Looking ahead, the company reaffirmed its full-year adjusted EPS guidance of $4.80 to $4.94, reflecting 1% to 4% growth from the reported figure of 2024, and maintained its revenue growth outlook of 2% to 4% for 2025.

Compared to its peer, Cardinal Health, Inc. (CAH) has notably outperformed HSIC stock. Shares of CAH have gained 38.5% on a YTD basis and climbed 58.8% over the past 52 weeks.

Among the 14 analysts covering the HSIC stock, the consensus rating is a “Moderate Buy.” Its mean price target of $76.54 suggests a 5.2% upside potential from current price levels.